title: Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants.
abstract: BACKGROUND
  Kidney transplantation from DCD now represents a significant part of the overall transplant activity in the UK. Outcome of different induction immunosuppression regimes and related cost benefit analysis has been reported by very few studies.This is a single centre study on frequency-matched patients who received a DCD kidney transplant between August 2007 and August 2009.
  
  
  METHODS
  Data on 45 patients divided in 2 groups were collected prospectively and analyzed retrospectively. Group A (24 patients) received IL2Mab and Group B (21 patients) ATG as induction immunosuppression. Patient and graft survival were similar in both groups.
  
  
  RESULTS
  In the ATG-induced group, there was a significant lower rate of DGF, BPAR, and infections requiring readmission.A cost analysis was performed including all immunosuppression-related costs, and it has shown remarkable savings in the ATG-induced group.
  
  
  CONCLUSIONS
  Considering that the number of DCD kidney transplants is destined to rise in the UK, we believe that ATG is a valid option to continue optimizing outcomes of DCD kidney transplant. In our experience, ATG proved to be safe, effective, and contributed to significant cost savings.
authors.affiliation: 1 Department of Renal Transplant Unit, Royal London Hospital, London, UK. 2 Address correspondence to: Asim Syed, Renal Transplant Unit, 9th Floor, Royal London Hospital, Whitechapel Road, London, E1 1BB.
authors.forename: Reena
authors.initials: R
authors.lastname: Popat
authors.forename: Asim
authors.initials: A
authors.lastname: Syed
authors.forename: Carmelo
authors.initials: C
authors.lastname: Puliatti
authors.forename: Roberto
authors.initials: R
authors.lastname: Cacciola
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D006085:Graft Survival; D017048:Health Care Costs; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000276:immunology; D016030:Kidney Transplantation / Q000191:economics* / Q000379:methods*; D061214:Patient Safety; D011446:Prospective Studies; D051437:Renal Insufficiency / Q000401:mortality / Q000628:therapy; D012189:Retrospective Studies; D014019:Tissue Donors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D007376:Interleukin-2